Health In Tech Latest Results: FY26 sales guidance affirmed at $45M-$50M
Health In Tech affirmed its FY2026 sales guidance at $45.000 million to $50.000 million, unchanged from its prior outlook. The analyst estimate of $46.813 million sits within the guided range. No upward or downward revision was made to the company's revenue target.
*this image is generated using AI for illustrative purposes only.
Health In Tech reaffirmed its FY2026 sales guidance, maintaining the range at $45.000 million to $50.000 million. The reaffirmation comes against an analyst estimate of $46.813 million, placing the consensus forecast within the company's guided band.
FY2026 sales guidance at a glance
The following table summarises Health In Tech's affirmed sales outlook against the prevailing analyst estimate.
| Metric: | Details |
|---|---|
| Guidance range (low): | $45.000 million |
| Guidance range (high): | $50.000 million |
| Analyst estimate: | $46.813 million |
The company made no change to its previously stated guidance range, reaffirming the $45.000 million to $50.000 million band for FY2026. The analyst consensus of $46.813 million falls within this range, indicating the estimate is broadly aligned with management's outlook.
What specific growth drivers or product lines is Health In Tech prioritizing to ensure it hits the upper end of its $50 million guidance range?
How might the alignment between management guidance and analyst estimates influence investor sentiment and stock volatility in the near term?
Are there any emerging macroeconomic risks or supply chain constraints that could threaten the company's ability to maintain this sales trajectory through FY2026?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
